B. Riley downgraded Longboard Pharmaceuticals to Neutral from Buy with a price target of $60, up from $45, after Lundbeck agreed to acquire Longboard for $60.00 per share in cash. The firm views the acquisition price as “highly reasonable,” particularly considering Longboard’s regulatory alignment for targeting a basket-style format for its pivotal program focused on DEEs, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Morning Movers: Longboard Pharmaceuticals surges following deal to be acquired
- Lundbeck to acquire Longboard Pharmaceuticals for $60.00 per share, or $2.6B
- Longboard Pharmaceuticals initiates DEEp SEA Study
- Longboard gets Rare Pediatric Disease, Orphan Drug designation for bexicaserin
- 3 Best Stocks to Buy Now, 9/18/2024, According to Top Analysts